Kudolo G B, DeFronzo R A
Department of Clinical Laboratory Sciences, School of Allied Health Sciences, University of Texas Health Science Center at San Antonio 78284-7772, USA.
Prostaglandins Other Lipid Mediat. 1999 May;57(2-3):87-98. doi: 10.1016/s0090-6980(98)00074-4.
Proteinuria is currently considered a very sensitive predictor of diabetic nephropathy, but 20-25% of all diabetic patients with negative Albustix reaction excrete higher than normal (< 20 mg/24 h) amounts of albumin in their urine. It is our hypothesis that platelet-activating factor (PAF), a potent glycerophospholipid that acts as a chemical mediator for a wide spectrum of biological activities, including increased vascular permeability, may be produced in significant amounts during periods preceding microalbuminuria. In this study, we compared urinary PAF excretion in Mexican-American subjects who were diagnosed with non-insulin dependent diabetes mellitus (NIDDM) with their healthy control counterparts. The age of the NIDDM subjects (45.9 +/- 2.1 years) was not significantly different from the healthy control group, which was 39.4 +/- 2.7 years (P < 0.0672). The NIDDM subjects (body mass index, 29.9 +/- 1.1 compared to 26.1 +/- 0.9 kg/m2 in healthy controls) were characterized by significantly increased (P < 0.05) fasting plasma glucose (192 +/- 11 vs. 97 +/- 4 mg/dl in healthy controls), fasting insulin (20.9 +/- 2.4 vs. 12.3 +/- 1.6 microU/ml), fasting C-peptide (2.93 +/- 1.26 vs. 1.48 +/- 0.51 ng/ml), and hemoglobin A1c (10.3 +/- 0.7 vs. 5.6 +/- 0.3%), respectively. The urine output for the NIDDM and control subjects were 1942 +/- 191 ml/24 h and 1032 +/- 94 ml/24 h, respectively, and urinary albumin excretion (UAE) rates were estimated to be 38 +/- 7 micrograms/min and 11 +/- 1 micrograms/min, respectively. The NIDDM subjects produced significantly increased levels of urinary PAF (2606.3 +/- 513.1 ng/24 h compared with 77.9 +/- 14.1 ng/24 h in controls (or 1706.3 +/- 420.8 ng/ml compared with 85.4 +/- 17.8 pg/ml of urine, in NIDDM and control subjects, respectively). We found that urinary PAF excretion was significantly correlated with microalbumin excretion (r = 0.7) especially at UAE rates greater than 30 mg/day and more importantly, some NIDDM patients with negative Albustix reaction (i.e. normal UAE) produced significantly more PAF, suggesting that PAF excretion may precede microalbuminuria and that subtle injury to the kidneys are present in NIDDM long before overt albuminuria ensues, urinary PAF measurements could potentially therefore serve as a sensitive indicator of renal injury in diabetes mellitus. These results lend further credence to our hypothesis that PAF may be the biochemical compound linking the various members of the insulin resistance syndrome.
蛋白尿目前被认为是糖尿病肾病非常敏感的预测指标,但在所有Albustix反应呈阴性的糖尿病患者中,有20% - 25%的患者尿中白蛋白排泄量高于正常水平(< 20 mg/24 h)。我们的假设是,血小板活化因子(PAF),一种强有力的甘油磷脂,作为多种生物活性的化学介质,包括增加血管通透性,可能在微量白蛋白尿出现之前大量产生。在本研究中,我们比较了被诊断为非胰岛素依赖型糖尿病(NIDDM)的墨西哥裔美国受试者与其健康对照者的尿PAF排泄情况。NIDDM受试者的年龄(45.9 ± 2.1岁)与健康对照组(39.4 ± 2.7岁)无显著差异(P < 0.0672)。NIDDM受试者(体重指数,29.9 ± 1.1,而健康对照组为26.1 ± 0.9 kg/m²)的特征是空腹血糖(192 ± 11 vs. 健康对照组97 ± 4 mg/dl)、空腹胰岛素(20.9 ± 2.4 vs. 12.3 ± 1.6 μU/ml)、空腹C肽(2.93 ± 1.26 vs. 1.48 ± 0.51 ng/ml)和糖化血红蛋白A1c(10.3 ± 0.7 vs. 5.6 ± 0.3%)显著升高(P < 0.05)。NIDDM和对照组受试者的尿量分别为1942 ± 191 ml/24 h和1032 ± 94 ml/24 h,尿白蛋白排泄(UAE)率分别估计为38 ± 7 μg/min和11 ± 1 μg/min。NIDDM受试者尿PAF水平显著升高(2606.3 ± 513.1 ng/24 h,而对照组为77.9 ± 14.1 ng/24 h;或分别为1706.3 ± 420.8 ng/ml和85.4 ± 17.8 pg/ml尿,NIDDM和对照组受试者)。我们发现尿PAF排泄与微量白蛋白排泄显著相关(r = 0.7),尤其是在UAE率大于30 mg/天时,更重要的是,一些Albustix反应呈阴性(即UAE正常)的NIDDM患者产生的PAF显著更多,这表明PAF排泄可能先于微量白蛋白尿,并且在NIDDM患者中,在明显蛋白尿出现之前很久肾脏就存在轻微损伤,因此尿PAF测量可能作为糖尿病肾病损伤的敏感指标。这些结果进一步支持了我们的假设,即PAF可能是连接胰岛素抵抗综合征各个成员的生化化合物。